Psoriasis Clinical Trial
Official title:
An Observational Study Evaluating the Utility of Ultrasound Confirmed Enthesitis as a Prognostic Marker for Response to Biologic Therapy in Psoriatic Arthritis
NCT number | NCT03955861 |
Other study ID # | 18046MR-SW |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | February 14, 2019 |
Est. completion date | July 17, 2021 |
Verified date | February 2022 |
Source | Belfast Health and Social Care Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The aim of this observational study will be to recruit 100 Psoriatic Arthritis (PsA) patients beginning on their biologic therapy and asses, both clinically and with the use of ultrasound (US), how enthesitis responds to biologic treatment. The decision to start treatment with a biologic therapy will be made by the patients' usual clinical rheumatology team, as part of their standard clinical care. This is independent of the study. Patients in whom treatment with these drugs for their PsA has been recommended will then be invited to participate in this study.They will then be commenced on biologic therapy at doses in line with the Summary of Product characteristics (SPC) for the product and followed up in the hospital outpatient clinic. Patients will have a full history taken and clinical exam performed prior to commencing on their prescribed biologic. The patient's history, Health Assessment Questionnaire scores and biobanking samples will be taken by the co-investigator. They will also calculate the patients tender and swollen joint score, dactylitis score, skin score, nail score and clinical enthesitis score.They will then have their tender entheseal points scanned as well as those as per the MASEI (Madrid Sonographic Enthesitis Index ) protocol by a single rheumatologist. The rheumatologist will be trained in ultrasound and will perform the scans blinded to this information both at initial consultation and at subsequent reviews. The patient will then commence their biologic treatment as planned at a separate review as per usual practise with their clinical team. Follow-up and final assessment at 4 months (±2 weeks) after starting biologic will include the clinical and ultrasound assessments as per the initial review and outlined in the schedule of assessments. They will also have a final blood sample taken at this point.
Status | Completed |
Enrollment | 80 |
Est. completion date | July 17, 2021 |
Est. primary completion date | July 17, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion criteria for PsA patients Patients with PsA will be included if they meet ALL of the following criteria: 1. Aged = 18 years 2. Fulfil the Classification criteria for PSA (CASPAR) 3. Have not previously had biologic disease modifying treatment for their PsA 4. Are due to commence on subcutaneous TNF inhibitor or secukinumab as part of their standard clinical care, in line with SPC for the product prescribed 5. Are able and willing to give informed consent and comply with the requirements of the study protocol NOTE: DMARD therapy will be permitted and used as per standard clinical practice Exclusion criteria: Patients will not be eligible if they meet ANY of the following criteria: 1. History of or current autoimmune rheumatic disease other than PsA 2. Previously received a biologic therapy for PsA 3. Receiving infliximab (IV TNF inhibitor) 4. Haemoglobin =9 g/dl 5. Known HUMAN immunodeficiency Virus (HIV), hepatitis C or B infection 6. Current oral steroids 7. Intramuscular steroids within 6 weeks of baseline (IA steroid injection will be allowed) assessment 8. Pregnancy or breast feeding 9. Subjects who are compulsorily detained for treatment of either a psychiatric or physical (e.g., infectious disease) illness. - |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Musgrave Park Hospital | Belfast | Antrim |
Lead Sponsor | Collaborator |
---|---|
Belfast Health and Social Care Trust | British Medical Association, Psoriasis and Psoriatic Arthritis Alliance, Queen's University, Belfast |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The change in Madrid enthesitis ultrasound index (MASEI) score | Ultrasound enthesitis response score. This is a validated tool for assessing enthesitis in spondyloarthropathy. It assess both chronic a active features of enthesitis at the knee, plantar fascia, achilles tendon and triceps tendon. A total score of 136 can be achieved. | 4 months | |
Secondary | The change in Minimal Disease Activity (MDA) response from baseline assessment | Composite clinical score for Psoriatic Arthritis. To be classified as MDA you need to achieve a score of at least 5/7 in the following parameters.
Swollen Joint count of = 1 of 66 Tender joint score of = 1 out of 68 Either a PASI (Psoriasis Area Severity Index) skin score = 15 or a Body Surface Score (BSA) of = 3% Patient Pain Visual Analogue Score (VAS) of = 15 Patient Global Disease Activity VAS of = 20 HAQ = 0.5 Tender Entheseal score of =1out of 6 as per the Leeds Enthesitis score |
4 months | |
Secondary | The change in Leeds Enthesitis Index (LEI) score from baseline assessment | Enthesitis clinical score that gives a score out of 6 based on clinical exam of entheseal sites at
Both Lateral Epicondyle of the Humerus Both Medial Condyle of the Femur Both Achilles insertion |
4 months | |
Secondary | The change in Dactylitis score from baseline assessment | Dactylitis is the uniform swelling of a whole digit such that the joints cannot be identified. Tenderness when examining dactylitis should be recorded. One dactylitic digit = one swollen joint and score is out of 20 for all five digits. | 4 months | |
Secondary | The change in 66/68 tender and swollen joint counts from baseline assessment | Validated tool to assess 68 sites for tender joints and 66 sites for swollen joints above and below the waist in Psoriatic Arthritis | 4 months | |
Secondary | The change in Psoriatic Arthritis Response Criteria (PsARC) response from baseline assessment | Composite disease activity score in Psoriatic Arthritis
The PsARC is defined as improvement in at least two of the following 4 criteria (one of which must be tender joint or swollen joint score) with no worsening of any criteria: 20% or more improvement in physician global assessment of disease activity 20% or more improvement in patient global assessment of disease activity 30% or more improvement in tender joint count 30% or more improvement in swollen joint count |
4 months | |
Secondary | Assess change in Ultrasound (US) findings at nail bed | Nail bed semi quantitative score changes looking at nail bed matrix thickness, nail plate morphology, colour doppler signal and nail bed thickness | 4 months | |
Secondary | Relationship of baseline MASEI score to the clinical outcomes at baseline | A regression analysis will be a carried out on the improvement in participant ultrasound enthesitis scores at 4 months with relation to clinical outcomes | 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |